ATE172880T1 - Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden - Google Patents

Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden

Info

Publication number
ATE172880T1
ATE172880T1 AT93113072T AT93113072T ATE172880T1 AT E172880 T1 ATE172880 T1 AT E172880T1 AT 93113072 T AT93113072 T AT 93113072T AT 93113072 T AT93113072 T AT 93113072T AT E172880 T1 ATE172880 T1 AT E172880T1
Authority
AT
Austria
Prior art keywords
treatment
bacterial meningitis
monoclonal anti
tnf antibodies
bacterial
Prior art date
Application number
AT93113072T
Other languages
English (en)
Inventor
Richard F Hector
Michael S Collins
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE172880T1 publication Critical patent/ATE172880T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT93113072T 1992-08-28 1993-08-16 Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden ATE172880T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93793992A 1992-08-28 1992-08-28

Publications (1)

Publication Number Publication Date
ATE172880T1 true ATE172880T1 (de) 1998-11-15

Family

ID=25470604

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93113072T ATE172880T1 (de) 1992-08-28 1993-08-16 Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden

Country Status (6)

Country Link
US (1) US5616321A (de)
EP (1) EP0585705B1 (de)
AT (1) ATE172880T1 (de)
DE (1) DE69321909T2 (de)
DK (1) DK0585705T3 (de)
ES (1) ES2121907T3 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
PT614984E (pt) † 1993-03-05 2001-12-28 Bayer Ag Anticorpos humanos anti-tnf
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2316852B1 (de) 2002-11-08 2014-03-05 Ablynx N.V. Stabilisierte Einzel-Domäne-Antikörper
CN100434440C (zh) * 2002-12-02 2008-11-19 阿布格尼克斯公司 针对肿瘤坏死因子的抗体及其用途
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
JP4484664B2 (ja) * 2003-11-27 2010-06-16 キヤノン株式会社 記録ヘッドカートリッジ
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
PL1888640T3 (pl) 2005-05-18 2012-08-31 Ablynx Nv Ulepszone nanociała skierowane przeciwko czynnikowi martwicy nowotworów typu alfa
EP3088410A3 (de) 2006-04-05 2016-12-28 AbbVie Biotechnology Ltd Antikörperreinigung
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP6175431B2 (ja) 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN104955480A (zh) 2013-01-25 2015-09-30 西蒙有限公司 用于选择性减少循环的生物活性可溶性tnf的组合物以及用于治疗tnf介导的疾病的方法
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP2803365A1 (de) 2013-05-14 2014-11-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Verwendung von Clonazepam in Verbindung mit Antibiotika bei der Behandlung von bakteriell verursachter Meningitis
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (de) 2015-04-10 2016-10-12 Ares Trading S.A. Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DE3888224T2 (de) * 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
EP0355067A1 (de) * 1988-08-19 1990-02-21 Celltech Limited Arzneimittel gegen bösartige Gewebeneubildung
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
WO1992003145A1 (en) * 1990-08-27 1992-03-05 Peptide Technology Ltd. Method of treating viral infection
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
AU668864B2 (en) * 1991-03-18 1996-05-23 Centocor Inc. Chimeric antibodies specific for human tumor necrosis factor
WO1994008619A1 (en) * 1992-10-08 1994-04-28 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
WO1995015179A1 (en) * 1993-12-01 1995-06-08 Unisearch Limited Method of treating intestinal disorders

Also Published As

Publication number Publication date
EP0585705B1 (de) 1998-11-04
EP0585705A1 (de) 1994-03-09
DE69321909D1 (de) 1998-12-10
DE69321909T2 (de) 1999-04-01
US5616321A (en) 1997-04-01
DK0585705T3 (da) 1999-07-26
ES2121907T3 (es) 1998-12-16

Similar Documents

Publication Publication Date Title
DE69321909D1 (de) Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
DE68927671D1 (de) Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
DE69233192D1 (de) Humanisierter antikörper gegen cd18
ATE117434T1 (de) Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
GR3026750T3 (en) Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein.
DE69221501T2 (de) Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen
DE69733960D1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
ATE155043T1 (de) Behandlung von autoimmun- und entzundungskrankheiten
GB9125768D0 (en) Therapeutic method
DE69424915D1 (de) Verwendung von 1-2-4-Benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
ATE120372T1 (de) Antikörper für die antilymphozyten- antikörpertherapie.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
DE69534601D1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
RU93004678A (ru) Противомикробные производные карбапенема, способы их получения и применение
ATE28214T1 (de) Malolaktisches gaerungsverfahren.
NO934655L (no) Legemiddel for gram-positive sykdommer i akvatiske arter
DE3773059D1 (de) Ester von salsalat mit guajakol zur behandlung von phlogistischen bronchopneumopathien.
DE69527868T2 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
DE59008759D1 (de) Verwendung von interleukin-2 zur behandlung der endotoxinämie.
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren
DE68924963T2 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
EA200101271A1 (ru) Блокирующее моноклональное антитело к vla-1 и его применение для лечения воспалительных заболеваний
TR199700791T1 (xx) Kendiliğinden bağışıklığı olan hastalıkların ve allograft rejeksiyonun tedavisi için LCK SH2 spesifik bileşimlerinin kullanılması.